Background: Human norovirus is a significant public health burden, with >30 genotypes causing endemic levels of disease and strains from the GII.4 genotype causing serial pandemics as the virus evolves new ligand binding and antigenicity features. During 2014-2015, genotype GII.17 cluster IIIb strains emerged as the leading cause of norovirus infection in select global locations. Comparison of capsid sequences indicates that GII.17 is evolving at previously defined GII.4 antibody epitopes. Methods: Antigenicity of virus-like particles (VLPs) representative of clusters I, II, and IIIb GII.17 strains were compared by a surrogate neutralization assay based on antibody blockade of ligand binding. Results: Sera from mice immunized with a single GII.17 VLP identified antigenic shifts between each cluster of GII.17 strains. Ligand binding of GII.17 cluster IIIb VLP was blocked only by antisera from mice immunized with cluster IIIb VLPs. Exchange of residues 393-396 from GII.17.2015 into GII.17.1978 ablated ligand binding and altered antigenicity, defining an important varying epitope in GII.17. Conclusions: The capsid sequence changes in GII.17 strains result in loss of blockade antibody binding, indicating that viral evolution, specifically at residues 393-396, may have contributed to the emergence of cluster IIIb strains and the persistence of GII.17 in human populations.
Background: Humannorovirus is a significant public health burden, with >30 genotypes causing endemic levels of disease and strains from the GII.4 genotype causing serial pandemics as the virus evolves new ligand binding and antigenicity features. During 2014-2015, genotype GII.17 cluster IIIb strains emerged as the leading cause of norovirus infection in select global locations. Comparison of capsid sequences indicates that GII.17 is evolving at previously defined GII.4 antibody epitopes. Methods: Antigenicity of virus-like particles (VLPs) representative of clusters I, II, and IIIb GII.17 strains were compared by a surrogate neutralization assay based on antibody blockade of ligand binding. Results: Sera from mice immunized with a single GII.17 VLP identified antigenic shifts between each cluster of GII.17 strains. Ligand binding of GII.17 cluster IIIb VLP was blocked only by antisera from mice immunized with cluster IIIb VLPs. Exchange of residues 393-396 from GII.17.2015 into GII.17.1978 ablated ligand binding and altered antigenicity, defining an important varying epitope in GII.17. Conclusions: The capsid sequence changes in GII.17 strains result in loss of blockade antibody binding, indicating that viral evolution, specifically at residues 393-396, may have contributed to the emergence of cluster IIIb strains and the persistence of GII.17 in human populations.
Authors: Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed Journal: Proc Natl Acad Sci U S A Date: 2012-05-21 Impact factor: 11.205
Authors: M de Graaf; J van Beek; H Vennema; A T Podkolzin; J Hewitt; F Bucardo; K Templeton; J Mans; J Nordgren; G Reuter; M Lynch; L D Rasmussen; N Iritani; M C Chan; V Martella; K Ambert-Balay; J Vinjé; P A White; M P Koopmans Journal: Euro Surveill Date: 2015-07-02
Authors: Lisa C Lindesmith; Eric F Donaldson; Martina Beltramello; Stefania Pintus; Davide Corti; Jesica Swanstrom; Kari Debbink; Taylor A Jones; Antonio Lanzavecchia; Ralph S Baric Journal: J Virol Date: 2014-05-28 Impact factor: 5.103
Authors: Jing Lu; Lin Fang; Huanying Zheng; Jiaqian Lao; Fen Yang; Limei Sun; Jianpeng Xiao; Jinyan Lin; Tie Song; Tao Ni; Jayna Raghwani; Changwen Ke; Nuno R Faria; Thomas A Bowden; Oliver G Pybus; Hui Li Journal: J Infect Dis Date: 2016-05-24 Impact factor: 5.226
Authors: Lisa C Lindesmith; Martina Beltramello; Eric F Donaldson; Davide Corti; Jesica Swanstrom; Kari Debbink; Antonio Lanzavecchia; Ralph S Baric Journal: PLoS Pathog Date: 2012-05-17 Impact factor: 6.823
Authors: Gabriel I Parra; R Burke Squires; Consolee K Karangwa; Jordan A Johnson; Cara J Lepore; Stanislav V Sosnovtsev; Kim Y Green Journal: PLoS Pathog Date: 2017-01-19 Impact factor: 6.823
Authors: Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Kari Debbink; Excel W Swann; Jan Vinjé; Ralph S Baric Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Claudia P Campillay-Véliz; Jonatan J Carvajal; Andrea M Avellaneda; Darling Escobar; Camila Covián; Alexis M Kalergis; Margarita K Lay Journal: Front Immunol Date: 2020-06-16 Impact factor: 7.561
Authors: Shilu Mathew; Khalid Alansari; Maria K Smatti; Hassan Zaraket; Asmaa A Al Thani; Hadi M Yassine Journal: Viruses Date: 2019-04-29 Impact factor: 5.048
Authors: Larissa Cristina Prado das Neves Costa; Dielle Monteiro Teixeira; Ana Caroline Rodrigues Portela; Ian Carlos Gomes de Lima; Renato da Silva Bandeira; Edivaldo Costa Sousa Júnior; Jones Anderson Monteiro Siqueira; Hugo Reis Resque; Luciana Damascena da Silva; Yvone Benchimol Gabbay Journal: BMC Infect Dis Date: 2019-12-02 Impact factor: 3.090